Ovarian cancer is the fourth leading cause of cancer among women and the number one gynecologic fatality. The etiology of ovarian cancer is still an enigma. Three common hypotheses under investigation include the ovulation, the pituitary gonadotropin, and the chronic inflammatory processes. Chemoprevention strategies used for ovarian cancer include oral contraceptives, aspirin and nonsteroidal anti-inflammatory agents, and retinoids. Surgical strategies are also used in the prevention of ovarian cancer. The primary treatment for patients with ovarian cancer is surgery with optimal tumor debulking, and for patients with advanced disease, this is followed by adjuvant chemotherapy. The standard practice is to follow surgery with six cycles of paclitaxel plus carboplatin. The second-line chemotherapy agents have had minimal long-term benefit for treating ovarian cancer. Hence, treatment with investigational agents remains the best option for patients with recurrent disease due to lack of alternative curative treatment.
Get full access to this article
View all access options for this article.
References
1.
1. Barnes MN, Grizzle WE, Grubbs CJ, Partridge EE. Paradigms for primary prevention of ovarian carcinoma . CA Cancer J Clin. 2002;52: 216-225 .
2.
2. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002 . CA Cancer J Clin. 2002;52: 23-47 .
3.
3. Partridge EE, Barnes MN. Epithelial ovarian cancer: prevention, diagnosis, and treatment . CA Cancer J Clin. 1999;49: 297-320 .
4.
4. Martin VR. Ovarian cancer . Semin Nurs Oncol. 2002;18: 174-183 .
5.
5. Runnebaum IB, Stickeler E. Epidemiological and molecular aspects of ovarian cancer risk . J Cancer Res Clin Oncol. 2001;127: 73-79 .
6.
6. Murdoch WJ, Lund SA. Prostaglandin-independent anovulatory mechanism of indomethacin action: Inhibition of tumor necrosis factor alpha-induced sheep ovarian cell apoptosis . Biol Reprod. 1999;61: 1655-1659 .
7.
7. Rodriguez GC, Wlamger DK, Cline M, et al. Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J Soc Gynecol Invest. 1998;5(5): 271-276 .
8.
8. Cramer DW, Harlow BL, Titus-Ernstoff L, Bohlke K, Welch WR, Greenberg ER. Over-the-counter analgesics and risk of ovarian cancer . Lancet. 1998;351: 104-107 .
9.
9. Tavani A, Gallus S, La Vecchia C, Conti E, Montella M, Franceschi S. Aspirin and ovarian cancer: an Italian case-control study . Ann Oncol. 2000;11: 1171-1173 .
10.
10. Cherry C, Vacchiano SA. Ovarian cancer screening and prevention . Semin Nurs Oncol. 2002;18(3): 167-173 .
11.
11. Streuwing JP, Watson P, Easton DF, Ponder BA, Lynch HT, Tucker MA. Prophylactic oophorectomy in inherited breast/ovarian cancer families . J Natl Cancer Inst Monogr. 1995;17: 33-35 .
12.
12. Piver MS, Jishi MF, Tsukada Y, Nava G. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer: a report of the Gilda Radner Familial Ovarian Cancer Registry . Cancer. 1993;71: 2751-2755 .
13.
13. Narod SA, Sun P, Ghadirian P, et al. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 and BRCA2 mutations: a case control study . Lancet. 2001;357: 1467-1470 .
14.
14. Stratton JF, Tidy JA, Paterson MEL. The surgical management of ovarian cancer . Cancer Treat Rev.2001:27; 111-118 .
15.
15. Colombo N, Guthrie D, Chiari S, et al. International collaborative ovarian neoplasme trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer . J Natl Cancer Inst. 2003;95(2): 125-132 .
16.
16. Covens A, Carey M, Bryson P, Shailendra V, Fung MFK, Johnston M. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer . Gynecol Oncol. 2002;85: 71-80 .
17.
17. Gore M. Treatment of relapsed epithelial ovarian cancer . ASCO Proceedings. 2001: 468-473 .
18.
18. Legros M, Daplat J, Fleury J, et al. High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long term results . J Clin Oncol. 1997;15(4): 1302-1308 .
19.
19. Morgan RJ, Doroshow JH, Leong L, et al. Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer . Bone Marrow Transplant. 2001;28(9): 859-863 .
20.
20. Stiff PJ, Bayer R, Kerger C, et al. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients . J Clin Oncol. 1997;15(4): 1309-1317 .
21.
21. Pedrazzoli P, Da Prada GA, Giorgiani G, et al. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies . Cancer. 2002;94(9): 2409-2415 .
22.
22. Alberts DS, Markman M, Armstrong D, Rothenberg ML, Muggia F, Howell SB. Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come! J Clin Oncol. 2002;20(19): 3944-3946 .
23.
23. Markman M. Intraperitoneal chemotherapy is appropriate first line therapy for patients with optimally debulked ovarian cancer . Crit Rev Oncol Hematol. 2001;38(3): 171-175 .
24.
24. White CA, Weaver RL, Grillo-Lopez AJ. Antibody-targeted immunotherapy for treatment of malignancy . Annu Rev Med. 2001;52: 125-145 .
25.
25. Hellstrom I, Goodman G, Pullman J, Yang Y, Hellstrom KE. Overexpression of HER-2 in ovarian carcinomas . Cancer Res. 2001;61(6): 2420-2423 .
26.
26. Cuello M, Ettenberg SA, Clark AS, et al. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2 . Cancer Res. 200161(12): 4892-4900 .
27.
27. Coukos, G. Gene therapy for ovarian cancer . Oncology. 2001;15(9): 1197-1208 .
28.
28. Hall AR, Dix BR, O'Carroll SJ, Braithwaite AW. p53-dependent cell death/apoptosis is required for a productive adenovirus infection . Nat Med. 1998;4: 1068-1072 .
29.
29. Tait DL, Obermiller PS, Redlin-Frazier S, et al. A phase I trial of retroviral BRCA1 sv gene therapy in ovarian cancer . Clin Cancer Res. 1997;3(11): 1959-1968 .
30.
30. Tait DL, Obermiller PS, Hatmaker AR.Relin-Frazier S, Holt JT. Ovarian cancer BRCA1 gene therapy: phase I and II trial differences in immune response and vector stability . Clin Cancer Res. 1999;5(7): 1708-1714 .
31.
31. Holt JT, Thompson ME, Szabo C, et al. Growth retardation and tumor inhibition by BRCA1 . Nat Genet. 1996;12: 298-302 .
32.
32. Hortobagyi GN, Ueno NT, Xia W, et al. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial . J Clin Oncol. 2001;19(14): 3422-3433 .
33.
33. Hung MC, Hortobagyi GN, Ueno NT. Development of clinical trial of E1A gene therapy targeting HER-2/neu-overexpressing breast and ovarian cancer . Adv Exp Med Biol. 2000;465: 171-180 .
34.
34. Hortobagyi GN, Hung MC, Lopez-Berstein G. A phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer . Hum Gene Ther. 1998;9(12): 1775-1798 .
35.
35. Martuza RL. Conditionally replicating herpes vectors for cancer therapy . J Clin Invest. 2000;105: 841-846 .
36.
36. Coukos G, Makrigiannakis A, Kang EH, et al. Use of carrier cells to deliver replication-selective herpes simplex virus-1 mutant for the intrapertioneal therapy of epithelial ovarian cancer . Clin Cancer Res. 1999;5: 1523-1537 .
37.
37. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. ONYX15, an E1B gene attenauted adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents . Nat Med. 1997;3: 639-645 .
38.
38. Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX15, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer . Nat Med. 2000;6: 879-885 .
